Innovative medicines in the Czech Republic are helping more and more people

Between 2010 and 2015, the number of patients treated with innovative drugs increased by almost 50 percent. The average cost per "central" patient remains stable despite the entry of new expensive drugs. Unfortunately, the Czech Republic is one of the slowest in Europe to make new medicines available to patients.

"According to foreign analyzes, new drugs have a third share in prolonging life expectancy. The share of patients treated with innovative drugs is still relatively low in the Czech Republic compared to Western European countries, but we can rejoice in the positive trend. From the point of view of access to the most modern treatment, we do not yet belong to the West, but at the same time not to the East, “sums up the situation by the pharmacoeconomist MUDr. Tomáš Doležal, Ph.D., from the iHETA Institute. According to him, new drugs against serious oncological, cardiovascular and metabolic diseases are the main contributors to the increase in life expectancy.

You can find the whole article here.